Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2012-07-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthermore the blood alcohol content (BAC) will be estimated by an official breathalyzer and one blood test.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This technology is non-invasive an can be measured by using conductive electrodes, capacitive electrodes or inductive measurement systems.
The BIS-values will be compared with an official breathanalyzer (Alcotest 7110 Evidential MK III, Dräger, Lübeck, Germany).
Furthermore one blood sample will be taken and analyzed with the ADH method as the current gold standard at the end of the trail.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bioimpedance measurements while trinking alcohol
Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
bioimpedance mesurements
Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bioimpedance mesurements
Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to give informed consent
* Inconspicuous laboratory and drug screening
Exclusion Criteria
* alcoholphobica, -allergy
* metallic ans / or electric implants
* underage persons
* interactively medication
18 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RWTH Aachen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Czaplik, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Department of Anaesthesiology ,Chair for Medical Information Technology Helmholtz Institute for Biomedical Engineering RWTH Aachen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anaesthesiology, University Hospital Aachen
Aachen, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-189
Identifier Type: -
Identifier Source: org_study_id